

County Durham and Tees Valley Area Prescribing Committee

Thursday 8th July 2021
9am – 11.30am
Held Via Microsoft Teams

Present

Name	Job Title	Membership Capacity	Organisation	Nov 2020	Mar 2021	May 2021	Jul 2021
David Russell	GP Prescribing Lead (Darlington)	Clinician	Tees Valley CCG	✓	✓	✓	✓
Angela Dixon	Medicines Optimisation Pharmacist	Pharmacist	Tees Valley CCG	✓	✓	✓	✓
Peter Foster	GP Prescribing Lead	Clinician	County Durham CCG	✓	✓	✓	✓
Kate Huddart	Senior Pharmaceutical Advisor	Pharmacist	County Durham CCG	✓ (Rachel Berry from item 10)	✓	✓	✓
Tim Rider	GP Prescribing Lead	Clinician	North Yorks CCG				
Susan Broughton	HRW Locality Lead Pharmacist	Pharmacist	North Yorks CCG	Chris Ranson	Chris Ranson	Chris Ranson	Chris Ranson
Rupert Smith	GP Prescribing Lead	Chair of FSG	Tees Valley CCG	✓	✓	✓	✓
Ian Davidson (Chair)	Medical Director	Clinician	County Durham CCG	✓	✓	✓	Apols
Janet Walker	Medical Director	Clinician	Tees Valley CCG	✓	✓	✓	✓
Shafie Kamaruddin	Consultant & Chair of CSTC	Clinician	CDDFT	✓ (items 3,5,& 25 only)	✓		✓
Jamie Harris	Chief Pharmacist	Pharmacist	CDDFT	✓	✓	✓	✓
		Clinician	NTHFT				
Chris Mallon	Formulary Pharmacist	Pharmacist	NTHFT	✓	✓	Apols	Confirmed happy with decisions via email
Andy Lloyd	Consultant & Chair of D&T	Clinician	STFT		✓ from item 5	✓	Apols
Helen Jones	Chief Pharmacist	Pharmacist	STFT	✓	✓	✓	Tracy Percival
Baxi Sinha		Clinician	TEWVFT	✓ (left after Item 12)	✓ (left after Item 25)	Apols	✓
Chris Williams	Chief Pharmacist	Pharmacist	TEWVFT	✓	✓	✓	✓
Julie Birch or Tanya Johnston	GP	LMC Rep		Tanya Johnston		Tanya Johnston	Apols
Rob Pitt	Community Pharmacist	LPC Rep – County Durham		✓ (from item 11)	✓	Apols	✓
Brent Foster	Community Pharmacist	LPC Rep – Tees					
Claire Jones	Public Health Pharmacist	Public Health Rep	Durham Council	Apols	Apols	✓	✓
Chris Cunnington - Shore		Service User Rep – County Durham		✓	✓	✓	✓

		Service User Rep - Tees					
Mark Pickering	Chief Finance Officer for Tees Valley CCG	Commissioning & Finance Rep	Tees Valley CCG	✓ (left after item 11)	Apols	✓	Apols
Rosie England	Chief Pharmacist	NEAS	NEAS				
Gavin Mankin	Principal Pharmacist Medicines Management	Professional Secretary	Regional Drug & Therapeutics Centre, Newcastle	✓	✓	✓	✓ + Dan Newsome

In attendance

Emily Brown – RDTC Admin Support – sharing papers via screen on MS Teams.

The meeting was chaired by Dr Shafie Kamaruddin.

The meeting was quorate and remained quorate throughout, with Chris Mallon confirming happy with decisions reached via email post meeting due to experiencing technical issues with IT during the meeting.

APC members and attendees were reminded to keep detailed discussions confidential to allow free and full debate to inform unencumbered decision-making. Discretion should be used when discussing meetings with non-attendees and papers should not be shared without agreement of the chair or professional secretary to ensure confidentiality is maintained.

Part 1

1. Apologies for Absence:

Ian Davidson, Mark Pickering, Helen Jones, Andy Lloyd, Tanya Johnston

2. Declarations of Interest

Declarations of interest:

The chair reminded subgroup members of their obligation to declare any interest they may have on any issue arising at committee meetings which might conflict with the business of the APC.

Declarations declared by members of the APC are listed in the APC's Register of Interests. The Register is available either via the professional secretary or on the APC website at:

<http://medicines.ncsu.nhs.uk/committees/durham-darlington-committees/>

Declarations of interest from sub committees:

None declared.

Declarations of interest from today's meeting:

None declared.

3. Minutes and Decision Summary of the Previous APC Meeting Held on 13th May 2021

The minutes were accepted as a true and accurate record.

The decision summary of the May 2021 meeting was accepted as a true and accurate record.

4. Matters Arising Not On the Agenda

Nil.

5. Action Log

APC Annual Report 2020/21

Version approved at May 2021 APC now added to website. ITEM NOW CLOSED.

TEVV Citalopram & Escitalopram - maximum dose reductions & ECG algorithm

Version approved at May 2021 APC still to be published on TEVV website.

Updated CD&T APC Shared Care Template

Link to approved version added to APC pages of NECS website and circulated. ITEM NOW CLOSED.

Implications of RMOC guidance on Local Shared Care Workstream

Update paper and proposal shared with other APCs in region, response awaited.

Guidance for Hypogonadism Management in Primary Care

Link to approved version added to APC pages of NECS website and the formulary. ITEM NOW CLOSED.

Boron additives in Chloramphenicol drops

CCG MO Teams to raise awareness of the issue with primary care prescribers. And await further guidance from MHRA.

CD&D DVT Pathway and Out of Hours Provision

Confirmed that CDDFT OOH services have access to rivaroxaban or can issue a late night prescription. Failing that they will give a dose of LMWH until a prescription can be dispensed.

Postcode/Interface Issues with other Formularies in Region

RDTG to work with NuTH Formulary Pharmacist to agree RAG position for an agreed list on tertiary centre drugs, and include the other APCs/Trusts as necessary. Emailed 7.7.21 & response awaited.

Joint Working With South Tyneside & Sunderland APC

CD&T APC Terms of Reference updating to reflect information sharing with South Tyneside & Sunderland APC, and their APC Secretary now receives the CD&T APC Agenda & Papers. ITEM NOW CLOSED.

RMOC Liothyronine Guidance

No further update due to COVID-19.

Algorithm for Blood Glucose Lowering Therapy in Adults with Type 2 Diabetes

Still await updated timescales for NICE updating their guidelines.

The regional diabetes clinical network are in the process of setting up a working group to try and progress.

Review of CD&T APC Terms of Reference

Chair written to NTFHT Medical Director to seek a clinical representative to APC, and response awaited.

Chris Mallon confirmed the representation issue has been flagged to pharmacy care group lead to discuss with the medical director a way forward as no progress been made.

Hydroxychloroquine SCG

Awaiting final RMOC South Guidance which was out for consultation in Oct 2020. Noted ongoing work within CCGs with providers on this and that RMOC draft shared care template for hydroxychloroquine in development this summer.

Northern England Evaluation and Lipid Intensification guideline

Awaiting final version to add to website.

Dapsone Shared Care Guideline

Link to approved version added to APC pages of NECS website and the formulary. ITEM NOW CLOSED.

Rivaroxaban in Preventing atherothrombotic events in people with Coronary or Peripheral Artery Disease (CAD/PAD)

SK has met with CDDFT cardiology and they have no appetite to produce a guideline as see it as a primary care prescribing issue. Also not a priority area at present. Noted that other APCs struggling to implement this NICE TA with a supporting guideline, and not aware of anywhere that has produced a guideline to for primary care to support this NICE TA. Agreed to keep on action log for now.

6. CD&TV APC Clinical Guideline or Pathway Approval Checklist

A proposed checklist to be used when submitting guidelines and shared care documents to the FSG/APC for approval to help improve the governance process and avoid some delays which have occurred was discussed and approved by the APC. It was noted that this checklist could replace the need for a cover sheet for guidelines being submitted to the APC for approval.

ACTION:

- **RDTDC to arrange for approved version to be added to APC pages of NECS website.**

Part 2 – Mental Health

7. TEWV Drug & Therapeutics Committee Feedback – May 2021

CW presented to the APC a briefing report highlighting the main issues discussed at the recent TEWV D&T.

8. TEWV STOMP medication pathway - draft

A draft pathway from TEWV designed to enhance the national guidance on STOMP providing greater advice for primary care was presented to and approved by the APC. It will also be shared with local learning disability networks.

ACTION:

- **RDTDC to arrange for link to approved version to be added to APC pages of NECS website and the formulary.**

9. TEWV Depression pathway (updated)

An updated TEWV Depression pathway was presented to and approved by the APC. It has been refreshed with changes to highlight key pieces of information and amend medication options at different steps.

ACTION:

- **RDTDC to arrange for link to approved version to be added to APC pages of NECS website and the formulary.**

10. TEWV Anxiety pathway (updated)

An updated TEWV Anxiety pathway was presented to and approved by the APC. It has been refreshed with changes to highlight key pieces of information and amend medication options at different steps.

ACTION:

- **RDTDC to arrange for link to approved version to be added to APC pages of NECS website and the formulary.**

11. TEWV Adult ADHD Algorithm (updated)

An updated TEWV Adult ADHD algorithm with some minor amendments was presented to and approved by the APC. The only change was to add Ritalin XL as a new product

ACTION:

- **RDTTC to arrange for link to approved version to be added to APC pages of NECS website and the formulary.**

12. TEWV Children’s ADHD Algorithm (updated)

An updated TEWV Children’s ADHD algorithm with some minor amendments was presented to and approved by the APC. The only change was to expand the information on when follow-ups regarding for patients on guanfacine.

ACTION:

- **RDTTC to arrange for link to approved version to be added to APC pages of NECS website and the formulary.**

13. TEWV Medication Safety Bulletin – Psychotropic drugs in overdose

Shared for information by TEWV.

14. TEWV Medication Safety – Tobacco smoking, smoking cessation & psychotropic drugs

Shared for information by TEWV. Noted that may be interest to community pharmacy and local stop smoking services so will share with them.

ACTION:

- **Trusts to share bulletin within their organisations to raise awareness.**
- **CJ to share with local stop smoking services.**
- **CCG MO Teams to include in their newsletter to GP practices.**

Part 3 – Formulary Issues

15. Appeals Against Previous APC Decisions

Nil for this meeting.

16. NICE TAs and MHRA Drug Safety Update – April & May 2021

These were presented to the group and the following actions were taken by the APC:

NICE Technology Appraisal/Guidance Title and date published	Date issued	Current formulary status	Recommended action for APC
<u>TA689: Acalabrutinib for treating chronic lymphocytic leukaemia</u> Commissioning: NHSE	21/04/21	No currently listed in chapter 8.1.5	Add as a RED drug and add link to NICE TA. The formulary will reflect the TAG.
<u>TA690: Teduglutide for treating short bowel syndrome (terminated appraisal)</u> Commissioning: NHSE	21/04/21	Not listed	No action. The formulary will reflect the TAG.
<u>TA691: Avelumab for untreated metastatic Merkel cell carcinoma</u> Commissioning: NHSE	21/04/21	Listed as RED drug in chapter 8.1.5 and 8.2.3	Move to chapter 8.2.3 and add link to NICE TA. The formulary will reflect the TAG.
<u>TA517 Avelumab for treating metastatic Merkel cell carcinoma</u> Commissioning: NHSE	21/04/21	Listed as RED drug in chapter 8.2.3	No action. The formulary will reflect the TAG.
<u>TA692: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy</u> Commissioning: NHSE	28/04/21	Listed as RED drug in chapter 8.1.5	Add link to NICE TA and that not recommended for this indication. The formulary will reflect the TAG.

TA693: Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer Commissioning: NHSE	28/04/21	Listed as RED drug in chapter 8.1.5	Add link to NICE TA. The formulary will reflect the TAG.
TA695: Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma Commissioning: NHSE	28/04/21	Listed as RED drug in chapter 8.1.5	Add link to NICE TA. The formulary will reflect the TAG
TA696: Tafamidis for treating transthyretin amyloidosis with cardiomyopathy Commissioning: NHSE	12/05/21	Not currently listed.	Add link to NICE TA and add as NOT APPROVED drug. The formulary will reflect the TAG.
TA694: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia Commissioning: CCG, tariff included.	28/04/21	Not currently listed.	Add link to NICE TA and add as GREEN drug. The formulary will reflect the TAG.
TA697: Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban Commissioning: CCG	12/05/21	Listed as NOT APPROVED in chapter 2.8.3 as per NTAG recommendation.	Change to RED drug and add link to NICE TA. The formulary will reflect the TAG.
TA698: Ravulizumab for treating paroxysmal nocturnal haemoglobinuria Commissioning: NHSE	19/05/21	Not currently listed in chapter 9.1.3a	Add link to NICE TA and add as RED drug. The formulary will reflect the TAG.
TA699: Ofatumumab for treating relapsing multiple sclerosis Commissioning: NHSE	19/05/21	Not currently listed in chapter 8.2.4	Add link to NICE TA and add as RED drug. The formulary will reflect the TAG.
TA700: Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal) Commissioning: NHSE	19/05/21	Not currently listed	No action required.
TA701: Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal) Commissioning: NHSE	19/05/21	Not currently listed in chapter 13.5.3	Add link to NICE TA and add as NOT APPROVED DRUG. The formulary will reflect the TAG.
TA702: Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal) Commissioning: NHSE	26/05/21	Listed as RED drug in chapter 8.1.5	Add link to NICE TA and NOT APPROVED for this indication. The formulary will reflect the TAG.
TA703: Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) Commissioning: NHSE	26/05/21	Listed as RED drug in chapter 8.1.5	Add link to NICE TA and NOT APPROVED for this indication. The formulary will reflect the TAG.
TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies Commissioning: NHSE	26/05/21	Not currently listed in chapter 8.1.5	Add link to NICE TA and add as NOT APPROVED drug. The formulary will reflect the TAG.

NG193: Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain	07/04/21	All relevant drugs on formulary.	Add link to start of Chapter 4. Any local pain guidelines will require a review and update – this is currently underway.
NG194: Postnatal care	20/04/21	No recommendations on specific drugs.	For information only
NG195: Neonatal infection: antibiotics for prevention and treatment	20/04/21	All antibiotics include in guidance on formulary.	Add link to start of chapter 5.
NG196: Atrial fibrillation: diagnosis and management	27/04/21	All relevant drugs on formulary.	Add link to start of chapter 2.
NG191: COVID-19 rapid guideline: managing COVID-19 (updated)	08/04/21 27/05/21	All relevant drugs on formulary.	Add link to start of chapter 5.
NG172: COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response (updated)	09/04/21	-	For information only.
NG169: COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response (updated)	09/04/21	-	For information only.
CG137: Epilepsies: diagnosis and management (updated)	12/05/21	-	For information only.
CG150: Headaches in over 12s: diagnosis and management (updated)	12/05/21	-	For information only.
ES36: Antimicrobial prescribing: nebulised liposomal amikacin	12/05/21	-	For information only.
NG88: Heavy menstrual bleeding: assessment and management (updated)	24/05/21	Awaiting new formulary application for ulipristal acetate (Esmya) for uterine fibroids	For information only.
Drug Safety Advice	Date issued	Current formulary status	Recommended action for APC
Polyethylene glycol (PEG) laxatives and starch-based thickeners: potential interactive effect when mixed, leading to an increased risk of aspiration	27/04/21	Listed as Green drugs in Chapter 1	Add link to MHRA DSU.
COVID-19 vaccines: updates for April 2021 A summary of advice recently issued by the MHRA relating to coronavirus (COVID-19), up to 21 April 2021.	27/04/21	n/a	For information only.
Letters and medicine recalls sent to healthcare professionals in March 2021	27/04/21	n/a	For information only.
Levothyroxine: new prescribing advice for patients who experience symptoms on switching between different levothyroxine products	19/05/21	Listed as GREEN drug in chapter 6.2.1	Add link to MHRA DSU.
COVID-19 vaccines: updates for May 2021 A summary of advice recently issued by the MHRA relating to coronavirus (COVID-19), up to 13 May 2021.	19/05/21	n/a	For information only.
Letters and medicine recalls sent to healthcare professionals in April 2021	19/05/21	n/a	For information only.

Requested formulary amendments	BNF Chapter	Reasoning	Recommended action for APC
Procyclidine 5mg/5ml oral liquid Commissioning: CCG, in tariff	4.9.2	Rosemont now also make a licensed 5mg/5ml which is more cost effective for larger doses. 2.5ml/5ml liquid currently listed as Amber SI on the formulary. Both products are licensed for the same indications.	Add as AMBER SI drug.
Simple Eye Ointment Commissioning: CCG, in tariff	11.8.1	To remove simple eye ointment from the formulary due to cost. Other significantly cheaper eye ointment used as ocular lubricants are available on the County Durham & Tees formulary.	To remove from formulary.
Denosumab 60mg injection (Prolia®) Commissioning: CCG, in tariff	6.6.2.2	To change wording on formulary to make clear that AMBER Specialist Initiation with first dose being given in secondary care.	To clarify that AMBER Specialist Initiation not Specialist Recommendation.
Fulvestrant injection Commissioning: NHSE, in tariff	8.3.4.1	To change the RAG status of Fulvestrant from NOT APPROVED to RED for those NICE TAs that permit use in combination with other agents (i.e. TA579, 691 & 687). To remain NOT APPROVED as per TA579 & TA593.	To change from NOT APPROVED to RED for those NICE TAs that permit use in combination with other agents (i.e. TA579, 691 & 687).
Hydrocortisone sodium phosphate 100mg/ml IM Injection (Efcortisol) Commissioning: CCG, in tariff	6.3.1	In County Durham & Tees Valley only the hydrocortisone sodium succinate (Solu-Cortef®) injection is listed in the formulary as a Green drug and this is the same as North of Tyne. Efcortisol is listed as not approved because the BNF lists as less suitable for prescribing as Paraesthesia and pain may follow intravenous injection.	To change from NOT APPROVED to a GREEN drug as an additional option to hydrocortisone sodium succinate for patients who are steroid dependant (pituitary or adrenal cause and occasionally non-endocrine reasons for long term steroid use) to manage sick day rules to avoid an Addisonian crisis.
Bosentan for digital ulcers Commissioning: NHSE, tariff excluded	2.5.1a	Formulary currently states that: NHS England – Not Routinely Commissioned for digital ulcers. There has been a change in NHSE policy Clinical Commissioning Policy: NHS England will now commission sildenafil and bosentan for patients requiring treatment of digital ulceration in systemic sclerosis in adults.	To add to formulary as RED for digital ulcers as per updated NHSE commissioning policy.

Isosorbide Mononitrate 60mg MR tablets Commissioning: CCG, in tariff	2.6.1	Modified release preparation requested for when compliance issues with ordinary twice daily tablets.	To add to formulary as a GREEN drug only when non-modified release are unsuitable e.g. to improved compliance.
New Formulary Applications	BNF Chapter	Reasoning	Recommended action for APC
Chloroprocaine Hydrochloride 1% Injection Commissioning: CCG, in tariff	15.2	For Spinal anaesthesia in adults where the planned surgical procedure should not exceed 40 minutes.	Approve as a RED drug.
Nystatin 100,000 Pessaries (unlicensed) Commissioning: CCG, in tariff	7.2.2	Requested as per BASHH guidelines for non-albicans vulvovaginal candida or inazole resistance	Approve as a RED drug.
Epiduo® Gel 0.3% (Adapalene/Benzyl Peroxide) Commissioning: CCG, in tariff	13.6.1	New strength for moderate to severe acne. Epiduo 0.1% available already for mild to moderate acne and listed on the formulary as a GREEN drug. Use lower strength for mild to moderate acne and reserve higher strength for more severe acne.	Approve as a GREEN drug
Diamorphine pre-filled syringes (unlicensed) Unlicensed Diamorphine 500 microgram in 0.5ml sodium chloride 0.9% intrathecal pre-filled syringe (1x0.5ml) – for intrathecal use Commissioning: CCG, in tariff	4.7.2	To reduce the risk of errors around the mixing of drugs for spinal anaesthesia.	Approve as a RED drug.

The APC noted the separate paper on the financial and commissioning implications of the update NICE Atrial Fibrillation guidelines in particular future anticoagulant monitoring clinic provision. It noted that discussions on implementation of the updated NICE AF guidelines are already underway locally.

ACTION:

- **RDTC to update the online formulary with the approved changes.**

17. New Drug Applications

Chloroprocaine Hydrochloride 1% Injection

Discussed under Item 16.

Nystatin Pessaries

Discussed under Item 16.

Epiduo® Gel (Adapalene/Benzyl Peroxide)

Discussed under Item 16.

Diamorphine pre-filled syringes (unlicensed) for use in spinal anaesthesia

Discussed under Item 16.

18. NTAG Update

Nil this month.

19. RMOC Update

RMOC Shared-Care Consultations

The APC noted the current shared care consultations on the RMOC website and

members/stakeholder organisations were asked to submit any comments on particular shared care guidelines directly to RMOC.

20. CDDFT CSTC Update

A verbal update on the last meeting was given. The APC noted that CDDFT is currently reviewing its choice of IV iron infusion preparation due to observing an increasing number of adverse drug reactions to their current choice.

21. NTHFT D&T Update

Nothing from D and T minutes to mention apart from concerns over Health Care at Home CQC report as have patients using their service.

22. STHFT D&T Update

Next meeting is next week.

23. Primary Care Prescribing Committee Updates

County Durham CCG – a verbal update was given
Tees Valley CCG – a verbal update was given.

Part 4 – Shared Care and Guidelines (non-Mental Health)

24. CD&T Dapagliflozin for Heart Failure Guideline

The final draft of new APC Guidance for Dapagliflozin for Heart Failure to support implementation of the NICE TA was presented to the APC and approved subject to the following amendments:

- Add all CDDFT and County Durham CCG logos.
- In Monitoring section, under Renal – further clarity required around how often periodic monitoring of renal function is recommended.
- Under Contra-indications: Type 1 diabetes – add in refer to diabetologist.

ACTION:

- **RDTC to request STHFT make the required amendments and then send to SK for Chair's action for approval.**
- **RDTC to arrange for approved version to be added to APC pages of NECS website.**

25. CD&T Guidance for Prescribing & Monitoring Post Bariatric Surgery

An updated version of CD&T Guidance for Prescribing & Monitoring Post Bariatric Surgery to match updated national guidelines was presented to the APC and approved.

ACTION:

- **RDTC to arrange for approved version to be added to APC pages of NECS website.**

26. CD&T Gluten Free Guidance

The existing local Gluten Free Guidance was due for review. The reviewed and updated version was presented to the APC and approved. It was agreed to adopt the updated guidance across County Durham & Tees Valley.

ACTION:

- **RDTC to arrange for approved version to be added to APC pages of NECS website.**

27. County Durham Bladder and Bowel Formulary

The existing County Durham Bladder and Bowel Formulary was due for review. The reviewed and updated version was presented to the APC and approved.

ACTION:

- **RDTC to arrange for approved version to be added to APC pages of NECS website.**

28. UACR Flowchart: approved

The diabetes Board for Durham CCG and Darlington PCN have requested approval of this flowchart based on the new NICE draft type 1 diabetes guidance. Urine Albumin-to-Creatinine Ratio (UACR) is used in Evaluating Patients with Diabetes for Kidney Disease. The flowchart was approved by the APC.

ACTION:

- **RDTTC to arrange for approved version to be added to APC pages of NECS website.**

29. GP clinical information sheet to support the prescribing and monitoring of Denosumab (Prolia®)

The final draft of a new APC GP clinical information sheet to support the prescribing and monitoring of Denosumab (Prolia®) was presented to the APC and approved. This supports the AMBER Specialist Initiation formulary status of Denosumab for osteoporosis.

ACTION:

- **RDTTC to arrange for approved version to be added to APC pages of NECS website.**

30. Amendment to CD&D DVT Pathway

The APC discussed and approved amending the current County Durham & Darlington DVT Pathway from October 2020 to allow the issue of up to 5 days' worth of DOAC initially whilst awaiting result of USS because CDDFT is currently unable to offer weekend USS to confirm DVTs.

ACTION:

- **Alda Hummelinck to amend CD&D DVT Pathway to allow the issue of up to 5 days' worth of DOAC initially whilst awaiting result of USS.**
- **RDTTC to arrange for updated version to be added to APC pages of NECS website.**

31. Updates to CD&T Respiratory Guidelines (COPD, Asthma, Paediatric Asthma)

The APC approved the minor updates and formulary changes as per the agenda item cover sheet.

ACTION:

- **RDTTC to arrange for approved version to be added to APC pages of NECS website.**
- **RDTTC to update the online formulary with the approved changes.**

32. Ergot derived dopamine agonists SCG

The existing Tees Ergot derived dopamine agonists in Parkinson's disease SCG was due for review. The reviewed and updated version was presented to the APC and approved. It was noted no changes were required to and that it will be adopted across County Durham & Tees Valley.

ACTION:

- **RDTTC to arrange for approved version to be added to APC pages of NECS website.**

33. Tolcapone in Parkinson's SCG

The existing Tees Tolcapone in Parkinson's disease SCG was due for review. The reviewed and updated version was presented to the APC and approved. It was noted no changes were required to and that it will be adopted across County Durham & Tees Valley.

ACTION:

- **RDTTC to arrange for approved version to be added to APC pages of NECS website.**

- 34. CDDFT SC Furosemide in Heart Failure Patients Approaching End of Life in the Acute or Community Setting Guideline**
Received for information.

Part 5 – Other Items of Business

- 35. Monitored Dosage Systems – New Recommendation Form, Review Form and Supporting Guidance for County Durham**

This guidance has been requested by the Elderly Care pharmacy team & Intermediate Care Pharmacy Technicians at CDDFT who highlighted concerns regarding the capacity for the dispensing of new MDS by community pharmacies in County Durham.

The aim of the recommendation form is to promote the appropriate use of an MDS by ensuring a thorough assessment of need is undertaken before a decision is made to provide an MDS.

The review form will ensure that processes are in place in primary care to review patients on an MDS as part of their annual review, provide a follow-up if trialling without an MDS and look to stop an MDS where they are no longer appropriate.

The guidance and associated forms were approved by the APC.

ACTION:

- **RDTC to arrange for approved version to be added to APC pages of NECS website.**

Part 6 – Standing Items (for information only)

- 36. Formulary Steering Group Minutes – April 2021**
For information.
- 37. TEWV D&T Minutes – March 2021**
For information.
- 38. CDDFT Clinical Standards and Therapeutics Committee Minutes – since April 2021**
Not yet available.
- 39. North Tees & Hartlepool Hospitals D&T Minutes – May 2021**
For information.
- 40. South Tees Hospitals D&T Minutes – May 2021**
For information.
- 41. RDTC Horizon Scanning – May & June 2021**
For information.
- 42. NTAG Minutes – February 2021**
For information.
- 43. NE&C CCG Prescribing Forum Minutes – April 2021**
For information.
- 44. NEAS Medicines Group Minutes – since November 2019**
Not yet available.
- 45. South Tyneside & Sunderland APC Minutes & Decision Summary – June 2021**
For information.

Chairman's Action

Nil this month.

Any Other Business

Choice of Brand of Enoxaparin used at CDDFT

The APC noted that CDDFT are changing the brand of Enoxaparin they currently use from Clexane® to the biosimilar Inhixa®.

Date and time of next meeting:

Thursday 9th September 2021, 9am – 11.30am, virtual meeting via Microsoft Teams tele/videoconference – details to be circulated